دورية أكاديمية
أعرض في EDS

Diabetes related phenotypes and their influence on outcomes of patients with corona virus disease 2019 (COVID-19).

التفاصيل البيبلوغرافية
العنوان: Diabetes related phenotypes and their influence on outcomes of patients with corona virus disease 2019 (COVID-19).
المؤلفون: Alves LI; Laboratório de Carboidratos e Radioimunoensaio LIM-18, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil., Bosco AA; Laboratório de Carboidratos e Radioimunoensaio LIM-18, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil., Rosa AA; Laboratório de Carboidratos e Radioimunoensaio LIM-18, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil., Correia MRS; Laboratório de Carboidratos e Radioimunoensaio LIM-18, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil., Matioli SR; Departamento de Genética e Biologia Evolutiva, Instituto de Biociências da Universidade de São Paulo, São Paulo, Brazil., da Silva MER; Laboratório de Carboidratos e Radioimunoensaio LIM-18, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. mbeth@usp.br.
مؤلفون مشاركون: HCFMUSP COVID-19 Study Group
المصدر: Diabetology & metabolic syndrome [Diabetol Metab Syndr] 2023 Oct 16; Vol. 15 (1), pp. 203. Date of Electronic Publication: 2023 Oct 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101488958 Publication Model: Electronic Cited Medium: Print ISSN: 1758-5996 (Print) Linking ISSN: 17585996 NLM ISO Abbreviation: Diabetol Metab Syndr Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central
مستخلص: Introduction: Diabetes mellitus (DM) is associated with severe forms of COVID-19 but little is known about the diabetes-related phenotype considering pre-admission, on-admission and data covering the entire hospitalization period.
Methods: We analyzed COVID-19 inpatients (n = 3327) aged 61.2(48.2-71.4) years attended from March to September 2020 in a public hospital.
Results: DM group (n = 1218) differed from Non-DM group (n = 2109) by higher age, body mass index (BMI), systolic blood pressure and lower O2 saturation on admission. Gender, ethnicity and COVID-19-related symptoms were similar. Glucose and several markers of inflammation, tissue injury and organ dysfunction were higher among patients with diabetes: troponin, lactate dehydrogenase, creatine phosphokinase (CPK), C-reactive protein (CRP), lactate, brain natriuretic peptide, urea, creatinine, sodium, potassium but lower albumin levels. Hospital (12 × 11 days) and intensive care unit permanence (10 × 9 days) were similar but DM group needed more vasoactive, anticoagulant and anti-platelet drugs, oxygen therapy, endotracheal intubation and dialysis. Lethality was higher in patients with diabetes (39.3% × 30.7%) and increased with glucose levels and age, in male sex and with BMI < 30 kg/m2 in both groups (obesity paradox). It was lower with previous treatment with ACEi/BRA in both groups. Ethnicity and education level did not result in different outcomes between groups. Higher frequency of comorbidities (hypertension, cardiovascular/renal disease, stroke), of inflammatory (higher leucocyte number, RCP, LDH, troponin) and renal markers (urea, creatinine, potassium levels and lower sodium, magnesium) differentiated lethality risk between patients with and without diabetes.
Conclusions: Comorbidities, inflammatory markers and renal disfunction but not Covid-19-related symptoms, obesity, ethnicity and education level differentiated lethality risk between patients with and without diabetes.
(© 2023. BioMed Central Ltd., part of Springer Nature.)
References: Front Public Health. 2021 Jul 07;9:591982. (PMID: 34307267)
Viruses. 2021 Nov 30;13(12):. (PMID: 34960670)
Front Endocrinol (Lausanne). 2023 Jan 19;14:1077959. (PMID: 36755914)
Diabetologia. 2021 Jul;64(7):1480-1491. (PMID: 33907860)
BMJ Open. 2021 May 4;11(5):e049089. (PMID: 33947740)
Front Endocrinol (Lausanne). 2021 Jun 17;12:649525. (PMID: 34220706)
Cell Metab. 2020 Sep 1;32(3):498-499. (PMID: 32877692)
Diabetologia. 2020 Aug;63(8):1500-1515. (PMID: 32472191)
Medicina (Kaunas). 2023 Jan 31;59(2):. (PMID: 36837480)
Mol Metab. 2020 Sep;39:101044. (PMID: 32585364)
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833. (PMID: 32798471)
Cardiovasc Res. 2020 Dec 1;116(14):2197-2206. (PMID: 33063089)
BMJ Glob Health. 2021 Apr;6(4):. (PMID: 33926892)
Endocrine. 2021 Jan;71(1):3-8. (PMID: 33179220)
PLoS One. 2020 Dec 10;15(12):e0243126. (PMID: 33301479)
PLoS One. 2022 Sep 28;17(9):e0275212. (PMID: 36170328)
Ir J Med Sci. 2023 Jun;192(3):1517-1523. (PMID: 35854192)
JAMA. 2023 Apr 11;329(14):1183-1196. (PMID: 37039790)
J Int Med Res. 2020 Jul;48(7):300060520939746. (PMID: 32722979)
PLoS One. 2021 Mar 18;16(3):e0248580. (PMID: 33735272)
Prim Care Diabetes. 2021 Aug;15(4):629-634. (PMID: 33849817)
Front Endocrinol (Lausanne). 2022 Aug 19;13:974540. (PMID: 36060943)
J Diabetes. 2021 Jan 23;:. (PMID: 33486896)
Diabetes Care. 2021 Dec;44(12):2790-2811. (PMID: 34711637)
Diabetes Res Clin Pract. 2022 Aug;190:109974. (PMID: 35809688)
Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166559. (PMID: 36174875)
فهرسة مساهمة: Investigator: TEP Barros-Filho; EM Utiyama; AC Segurado; B Perondi; AC Montal; L Harima; SRG Fusco; MF Silva; MC Rocha; IC Rios; FYO Kawano; MA Jesus; E Kallas; MCPB Francisco; CMD Carmo; C Tanaka; MS Oliveira; T Guimarães; CDS Lázari; MMC Magri; JFM Marchini; AJDS Duarte; EC Sabino; SF Costa; AM Morais; HP Souza; CRR Carvalho; JC Ferreira; ASS Levin
Keywords: COVID-19; Clinical data; Diabetes; Laboratory data; Outcome
تواريخ الأحداث: Date Created: 20231016 Latest Revision: 20231121
رمز التحديث: 20231121
مُعرف محوري في PubMed: PMC10577940
DOI: 10.1186/s13098-023-01168-w
PMID: 37845766
قاعدة البيانات: MEDLINE
الوصف
تدمد:1758-5996
DOI:10.1186/s13098-023-01168-w